Novus Biologicals products are now on bio-techne.com

Sort By:

Products (4)

page of 1

Netrin-G1a Antibodies

We offer Netrin-G1a Antibodies for use in common research applications: Western Blot. Each Netrin-G1a Antibody is fully covered by our Guarantee+, to give you complete peace of mind and the support when you need it. Our Netrin-G1a Antibodies can be used in a variety of model species: Mouse. Use the list below to choose the Netrin-G1a Antibody which is most appropriate for your research; you can click on each one to view full technical details, images, references, reviews and related products. Choose from our Netrin-G1a polyclonal antibodies and browse our Netrin-G1a monoclonal antibody catalog.

Alternate Names for Netrin-G1a Antibodies

anti-Netrin-G1a antibody, anti-Ntng1 antibody

4 Results for "netrin-g1a" in Primary Antibodies

AF1166

Netrin-G1a Antibody [Unconjugated]

(7 Publications)

100 μg

AF1166

Transient expression of Cyp26b1 in the PFC does not occur in the absence of thalamus–cortex interactions in Gbx2 mutant mice. A–F, Thalamus–PFC disconnection in Gbx2 mutant mice. A, B, Immunostaining for NetrinG1 at E16.5. In control mice, NetrinG1-labeled thalamocortical axons are visible in coronal sections of frontal cortex. Arrowhead in A shows the medial PFC, where robust labeling is detected. In contrast, NetrinG1 labeling is barely detectable in the frontal cortex of Gbx2 mutant mice, including the medial PFC (B, arrowhead). Scale bar, 200 µm. C–F, DiI labeling at P14. C, D, DiI placement in medial PFC retrogradely labels medial thalamic nuclei in the control brains. E, F, In Gbx2 mutants, the label is severely reduced, indicating the deficiency of both thalamocortical and corticothalamic projections. G–J, Expression of ROR beta and Lmo4 is qualitatively normal in the PFC of Gbx2 mutant mice at P8. G, I, The expression of ROR beta in layer 4 is comparable between control (G) and Gbx2 mutant (cko) mice (I, arrows). H, J, Laminar expression patterns of Lmo4 also appear unchanged in Gbx2 mutants. Scale bar, 1 mm. K–Z, Transient expression of Cyp26b1 in the PFC does not occur in the absence of thalamus–cortex interactions in Gbx2 mutant mice. K–T, in situ hybridization of frontal sections through PFC at various postnatal stages with a Cyp26b1 probe. K–O, In control mice (K–O), Cyp26b1 expression starts at P2 in medial (K, arrowhead) and ventral (K, single arrow) PFC, and continues until P14 (M). N, O, At P21, expression in medial PFC is reduced (N) and is no longer detectable at P35 (O). K–O, In addition to medial and ventral PFC, Cyp26b1 is also expressed in lateral frontal cortex, including the motor and somatosensory areas (double arrows) and agranular insula (double arrowheads). P–T, In Gbx2 mutant mice, the expression of Cyp26b1 is not induced in medial or ventral PFC at P2 as well as at later stages, although ventral PFC does not appear to be affected at P14 and later. P–T, Expression in more superficial layer of lateral cortex (double arrows and double arrowheads) is not affected in Gbx2 mutant mice. U, X, Expression of the layer 6 marker Syt6 is not affected in Gbx2 mutant mice. V, Y, Expression of Aldh1a3 in layer 2 of medial PFC and anterior cingulate cortex (arrow) is not affected in Gbx2 mutant mice. Scale bar, 1 mm. W, Z, Summary schematic for this figure. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/30868103), licensed under a CC-BY license. Not internally tested by R&D Systems.

Normal induction of Cyp26b1 in PFC in mice expressing tetanus toxin light chain in thalamocortical axons. A–D, Immunostaining for VAMP2 on frontal sections of somatosensory cortex at E16.5 control (A, B) and mutant mice with ectopic expression of TeNT in thalamic neurons (C, D). TeNT expression leads to the deletion of VAMP2, specifically in thalamocortical axons at E16.5. Thalamocortical axons are shown by NetrinG1 staining (B, D, green). In control brains, both thalamocortical (bracket, A–D) and corticofugal (asterisk, A–D) axons express VAMP2, whereas in TeNT-expressing mice, VAMP2 staining is specifically diminished in thalamocortical axons (C, D, bracket). Scale bar, 500 μm. E, F, Deletion of VAMP2 in thalamocortical axons results in the lack of the characteristic pattern of ROR beta expression in the barrel field of primary somatosensory cortex at P8 (arrow), similar to the defect found in Gbx2 mutant mice (Vue et al., 2013). G–J, Immunostaining for VAMP2 on frontal sections of prefrontal cortex at P0 control (G, H) and mutant mice with ectopic expression of TeNT in thalamic neurons (I, J). Similar to the somatosensory cortex, VAMP2 staining in thalamocortical axons is diminished in TeNT-expressing mice (I, J, bracket). Scale bar, 200 μm. K, L, Expression of Cyp26b1 in medial (arrowhead) and ventral PFC is intact in TeNT-expressing mice (L), similar to control (K), at P8. Scale bars: G, H, I, J, 200 μm; E, F, K, L, 1 mm. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/30868103), licensed under a CC-BY license. Not internally tested by R&D Systems.

Transient expression of Cyp26b1 in the PFC does not occur in the absence of thalamus–cortex interactions in Gbx2 mutant mice. A–F, Thalamus–PFC disconnection in Gbx2 mutant mice. A, B, Immunostaining for NetrinG1 at E16.5. In control mice, NetrinG1-labeled thalamocortical axons are visible in coronal sections of frontal cortex. Arrowhead in A shows the medial PFC, where robust labeling is detected. In contrast, NetrinG1 labeling is barely detectable in the frontal cortex of Gbx2 mutant mice, including the medial PFC (B, arrowhead). Scale bar, 200 µm. C–F, DiI labeling at P14. C, D, DiI placement in medial PFC retrogradely labels medial thalamic nuclei in the control brains. E, F, In Gbx2 mutants, the label is severely reduced, indicating the deficiency of both thalamocortical and corticothalamic projections. G–J, Expression of ROR beta and Lmo4 is qualitatively normal in the PFC of Gbx2 mutant mice at P8. G, I, The expression of ROR beta in layer 4 is comparable between control (G) and Gbx2 mutant (cko) mice (I, arrows). H, J, Laminar expression patterns of Lmo4 also appear unchanged in Gbx2 mutants. Scale bar, 1 mm. K–Z, Transient expression of Cyp26b1 in the PFC does not occur in the absence of thalamus–cortex interactions in Gbx2 mutant mice. K–T, in situ hybridization of frontal sections through PFC at various postnatal stages with a Cyp26b1 probe. K–O, In control mice (K–O), Cyp26b1 expression starts at P2 in medial (K, arrowhead) and ventral (K, single arrow) PFC, and continues until P14 (M). N, O, At P21, expression in medial PFC is reduced (N) and is no longer detectable at P35 (O). K–O, In addition to medial and ventral PFC, Cyp26b1 is also expressed in lateral frontal cortex, including the motor and somatosensory areas (double arrows) and agranular insula (double arrowheads). P–T, In Gbx2 mutant mice, the expression of Cyp26b1 is not induced in medial or ventral PFC at P2 as well as at later stages, although ventral PFC does not appear to be affected at P14 and later. P–T, Expression in more superficial layer of lateral cortex (double arrows and double arrowheads) is not affected in Gbx2 mutant mice. U, X, Expression of the layer 6 marker Syt6 is not affected in Gbx2 mutant mice. V, Y, Expression of Aldh1a3 in layer 2 of medial PFC and anterior cingulate cortex (arrow) is not affected in Gbx2 mutant mice. Scale bar, 1 mm. W, Z, Summary schematic for this figure. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/30868103), licensed under a CC-BY license. Not internally tested by R&D Systems.

Transient expression of Cyp26b1 in the PFC does not occur in the absence of thalamus–cortex interactions in Gbx2 mutant mice. A–F, Thalamus–PFC disconnection in Gbx2 mutant mice. A, B, Immunostaining for NetrinG1 at E16.5. In control mice, NetrinG1-labeled thalamocortical axons are visible in coronal sections of frontal cortex. Arrowhead in A shows the medial PFC, where robust labeling is detected. In contrast, NetrinG1 labeling is barely detectable in the frontal cortex of Gbx2 mutant mice, including the medial PFC (B, arrowhead). Scale bar, 200 µm. C–F, DiI labeling at P14. C, D, DiI placement in medial PFC retrogradely labels medial thalamic nuclei in the control brains. E, F, In Gbx2 mutants, the label is severely reduced, indicating the deficiency of both thalamocortical and corticothalamic projections. G–J, Expression of ROR beta and Lmo4 is qualitatively normal in the PFC of Gbx2 mutant mice at P8. G, I, The expression of ROR beta in layer 4 is comparable between control (G) and Gbx2 mutant (cko) mice (I, arrows). H, J, Laminar expression patterns of Lmo4 also appear unchanged in Gbx2 mutants. Scale bar, 1 mm. K–Z, Transient expression of Cyp26b1 in the PFC does not occur in the absence of thalamus–cortex interactions in Gbx2 mutant mice. K–T, in situ hybridization of frontal sections through PFC at various postnatal stages with a Cyp26b1 probe. K–O, In control mice (K–O), Cyp26b1 expression starts at P2 in medial (K, arrowhead) and ventral (K, single arrow) PFC, and continues until P14 (M). N, O, At P21, expression in medial PFC is reduced (N) and is no longer detectable at P35 (O). K–O, In addition to medial and ventral PFC, Cyp26b1 is also expressed in lateral frontal cortex, including the motor and somatosensory areas (double arrows) and agranular insula (double arrowheads). P–T, In Gbx2 mutant mice, the expression of Cyp26b1 is not induced in medial or ventral PFC at P2 as well as at later stages, although ventral PFC does not appear to be affected at P14 and later. P–T, Expression in more superficial layer of lateral cortex (double arrows and double arrowheads) is not affected in Gbx2 mutant mice. U, X, Expression of the layer 6 marker Syt6 is not affected in Gbx2 mutant mice. V, Y, Expression of Aldh1a3 in layer 2 of medial PFC and anterior cingulate cortex (arrow) is not affected in Gbx2 mutant mice. Scale bar, 1 mm. W, Z, Summary schematic for this figure. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/30868103), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reactivity:

Mu

Species Glossary

Reactivity: Mu

Applications:

Applications:

Host:

Goat Polyclonal

Host: Goat Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	AF1166-SP

compare

(select up to 3 products from this page to compare)

MAB10019

Netrin-G1a Antibody (1010035) [Unconjugated]

100 μg

MAB10019

HEK293 human embryonic kidney cell line transfected with Netrin-G1a (filled histogram) or irrelevant protein (open histogram) was stained with Mouse Anti-Human Netrin-G1a Monoclonal Antibody (Catalog # MAB10019) followed by APC-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). View our protocol for Staining Membrane-associated Proteins.

U87-MG human glioblastoma cell line was stained with Mouse Anti-Human Netrin-G1a Monoclonal Antibody (Catalog # MAB10019) or isotype control antibody (Catalog # MAB002, open histogram) followed by APC-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). View our protocol for Staining Membrane-associated Proteins.

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

,

Applications: ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 532	FAB10019X
Allophycocyanin	FAB10019A
Allophycocyanin/Cy7	FAB10019APCCY7
Biotin	FAB10019B
CoraFluor 1	FAB10019CL1
DyLight 350	FAB10019D
DyLight 405	FAB10019E
DyLight 488	FAB10019K
DyLight 550	FAB10019L
DyLight 594	FAB10019M
DyLight 650	FAB10019W
DyLight 680	FAB10019Y
DyLight 755	FAB10019Z
FITC	FAB10019F
HRP	FAB10019H
Janelia Fluor 525	FAB10019JF525
Janelia Fluor 549	FAB10019I
Janelia Fluor 646	FAB10019J
Janelia Fluor 669	FAB10019JF669
PE	FAB10019P
PE/Atto594	FAB10019PEATT594
PE/Cy5.5	FAB10019PECY55
PE/Cy7	FAB10019PECY7
PerCP	FAB10019C
mFluor Violet 450 SE	FAB10019MFV450
mFluor Violet 500 SE	FAB10019MFV500
mFluor Violet 610 SE	FAB10019MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	MAB10019-SP

compare

(select up to 3 products from this page to compare)

MAB1166

Netrin-G1a Antibody (229722)

500 μg

Reactivity:

Mu

Species Glossary

Reactivity: Mu

Applications:

Applications:

Host:

Rat Monoclonal

Host: Rat Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	MAB1166-SP

compare

(select up to 3 products from this page to compare)

FAB10019JF669

Netrin-G1a Antibody (1010035) [Janelia Fluor® 669]

0.1 ml

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

,

Applications: ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Conjugate:

Janelia Fluor 669

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	FAB10019U-100UG
Alexa Fluor 405	FAB10019V-100UG
Alexa Fluor 488	FAB10019G-100UG
Alexa Fluor 532	FAB10019X
Alexa Fluor 594	FAB10019T-100UG
Alexa Fluor 647	FAB10019R-100UG
Alexa Fluor 700	FAB10019N-100UG
Alexa Fluor 750	FAB10019S-100UG
Allophycocyanin	FAB10019A
Allophycocyanin/Cy7	FAB10019APCCY7
Biotin	FAB10019B
CoraFluor 1	FAB10019CL1
DyLight 350	FAB10019D
DyLight 405	FAB10019E
DyLight 488	FAB10019K
DyLight 550	FAB10019L
DyLight 594	FAB10019M
DyLight 650	FAB10019W
DyLight 680	FAB10019Y
DyLight 755	FAB10019Z
FITC	FAB10019F
HRP	FAB10019H
Janelia Fluor 525	FAB10019JF525
Janelia Fluor 549	FAB10019I
Janelia Fluor 585	FAB10019JF585
Janelia Fluor 635	FAB10019JF635
Janelia Fluor 646	FAB10019J
PE	FAB10019P
PE/Atto594	FAB10019PEATT594
PE/Cy5.5	FAB10019PECY55
PE/Cy7	FAB10019PECY7
PerCP	FAB10019C
mFluor Violet 450 SE	FAB10019MFV450
mFluor Violet 500 SE	FAB10019MFV500
mFluor Violet 610 SE	FAB10019MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	MAB10019-100
Carrier Free	MAB10019-SP
Carrier Free	FAB10019V-100UG
Carrier Free	FAB10019U-100UG
Carrier Free	FAB10019T-100UG
Carrier Free	FAB10019S-100UG
Carrier Free	FAB10019R-100UG
Carrier Free	FAB10019N-100UG
Carrier Free	FAB10019G-100UG

compare

(select up to 3 products from this page to compare)

page of 1

Popular Products	Company Information	Support	Stay Connected
Antibodies Secondary Antibodies Isotype Controls Proteins and Peptides ELISA Kits Sample Size New Products	About Us Careers Novus Guarantee Contact Us Our Team	Technical Support FAQs Help Finding Antibodies Protocols

Visit our other sites

©2024 Novus Biologicals, All Rights Reserved.